Update on Sexual Dysfunction Associated with Psychotropic Medications and Its Treatment
Purpose of Review
The goal of this review was to evaluate recent developments in sexual dysfunction associated with psychotropic medications and its management.
Sexual dysfunction associated with psychotropic medications is a serious clinical problem which occurs mostly with antidepressants, especially serotonergic ones, and antipsychotics, especially those causing hyperprolactinemia. Sexual dysfunction(s) seems to be associated to a significantly lesser degree with some newer psychotropic medications, e.g., vilazodone, vortioxetine, and agomelatine among antidepressants, and aripiprazole and lurasidone among antipsychotics. There have been no significant new developments in management of sexual dysfunction(s) associated with psychotropic medications with the exception of using newer medications or switching to them. A new clinical phenomenon—post serotonin reuptake inhibitors sexual dysfunction—has emerged as a difficult management issue.
Sexual dysfunction associated with psychotropic medications continues to be an important issue requiring further research to provide solid evidence for regulatory agencies and for clinicians.
KeywordsSexual dysfunction Antidepressants Antipsychotics Post-SSRI sexual dysfunction
Compliance with ethical standards
Conflict of Interest
The author declares that he has no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Segraves RT, Balon R. Sexual pharmacology: fast facts. New York: WW Norton, Inc.; 2003.Google Scholar
- 6.• Clayton AH, McGarvey L, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability and validity. Psychopharmacol Bull. 1997;33:731–45 This article provides information on reliability and validity of the most established scale used for evaluating sexual dysfunction with psychotropic medication. Google Scholar
- 8.•• Jacobsen P, Mahableshwarkar MD, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12:2036–48 This study demonstrated lower frequency of sexual dysfunction associated with vortioxetine when compared to escitalopram.CrossRefGoogle Scholar
- 9.• Clayton AH, Durgam S, Li D, Chen C, Chan L, Mathews M, et al. Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study. Int Clin Psychopharmacol. 2017;32:27–35 This study demonstrated lesser nonsignificant impact of vilazodone on sexual function than paroxetine in healthy volunteers.CrossRefGoogle Scholar
- 10.• Montejo AL, Deakin JFW, Gaillard R, Harmer C, Meyniel F, Jabourian A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitaloptam (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. J Psychopharmacol. 2015;29:1119–28 This study demonstrated significantly lower impact of agomelatine on sexual functioning when compared to escitalopram in healthy volunteers.Google Scholar
- 12.Bijlsma EY, Chan JSW, Olivier B, Veening JG, Millan MJ, Waldinger MD, et al. Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacology, Biochemistry and Behavior. 2014;121:88–101.Google Scholar
- 18.•• Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300:395–404 This study demonstrated possible use of sildenafil in sexual dysfunction associated with antidepressants in women. CrossRefGoogle Scholar
- 20.Modabbernia A, Sohrabi H, Nasehi AA, Raisi F, Saroukhani S, Jamshidi A, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized, double-blind, placebo-controlled trial. Psychopharmacol. 2012;223:381–8.Google Scholar
- 23.Farnia V, Shirzadifar M, Shakeri J, Rezaei M, Bajoghli J, Holsboer-Trachsler E, et al. Rosa damascene oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial. Neuropsychiatr Dis Treat. 2015;11:625–35.Google Scholar
- 25.Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwijekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;5:CD003382.Google Scholar
- 27.Fujioji J, Iwamoto K, Banno M, Kikuchi T, Aleksic B, Ozaki N. Effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia: a preliminary open-label study. Pharmacopsychiatry. 2017;50:74–8.Google Scholar
- 28.•• Potkin SG, Loze JY, Forray C, Baker RA, Sapin C, Peters-Strickland T, et al. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. Int Clin Psychopharmacol. 2017;32:147–54 This study showed that aripiprazole once monthly is associated with less sexual dysfunction and less hyperprolactinemia than paliperidone palmitate.CrossRefGoogle Scholar
- 29.• McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25–40 Demonstration of reliability and validity of another frequently used tool to evaluate sexual dysfunction with psychotropic medications.CrossRefGoogle Scholar
- 30.• Clayton AH, Tsai J, Mao Y, Pikalov A, Loebel A. Effect of lurasidone on sexual function in major depressive disorder patients with subthreshold hypomanic symptoms (mixed features): results from a placebo-controlled trial. J Clin Psychiatry. 2018;79(5):23–9 This study demonstrated low frequency of sexual dysfunction with a new antipsychotic lurasidone. CrossRefGoogle Scholar
- 31.• Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, et al. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin Neuropharmacol. 2016;39:288–94 New approach to sexual dysfunction associated with antipsychotics.Google Scholar
- 34.Khin NA, Kronstein PD, Yang P, Ishida E, Hung HMJ, Mathis MV, et al. Regulatory and scientific issue in studies to evaluate sexual dysfunction in antidepressant drug trials. J Clin Psychiatry. 2015;76:1060–3.Google Scholar
- 36.•• Bala A, HMT N, Hellstrom WJG. Post-SSRI sexual dysfunction: a literature review. Sex Med Rev. 2018;6:29–34 This article reviews an emerging difficult to manage this clinical phenomenon.Google Scholar
- 37.Waldinger MD, van Coevorden RS, Schweitzer DH, Georgiadis J. Penile anesthesia in post SSRI sexual dysfunction (PSSD) responds to low-power laser irradiation: a case study and hypothesis about the role of transient receptor potential (TRP) in channels. Eur J Pharmacol. 2015;753:263–8.CrossRefGoogle Scholar
- 38.Calabro RS, De Luca R, Manuli A, Portaro S, Naro A, Quattrini F. Rowards improving post-SSRI dysfunction by using nutriceuticals: lessons from a case study. J Sex marital Ther 2019 Jan. 14:1–4. https://doi.org/10.1080/0092623X2018.1556755.